Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

October 2011

Clinical Trials, Cohort Studies, Pilot Studies                              1 - 9 

Basic and Applied Science, Pre-Clinical Studies              9 - 11

HIV/HCV Coinfection                                                              12 - 17

Complementary and alternative medicine                                   18

Epidemiology, Diagnostics & Miscellaneous Works                18 - 21

Liver Cancer                                                                              21 - 24

Clinical Trials, Cohort Studies, Pilot Studies

Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C.

Perzynski AT, McCormick R, Webster NJ, et al. J Stud Alcohol Drugs. 2011 Sep;72(5):787-98.

http://www.ncbi.nlm.nih.gov/pubmed/21906506

Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy. Muazzam AG, Qureshi S, Mansoor A, et al. Genet Vaccines Ther. 2011 Sep 6;9(1):14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21892969

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients with Chronic HCV infection. Zeuzem S, Asselah T, Angus P, et al. Gastroenterology. 2011 Sep 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21925126

Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.

Floreani A, Cazzagon N, Boemo DG, et al. Eur J Gastroenterol Hepatol. 2011 Sep 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21915057

Response-guided telaprevir combination treatment for hepatitis C virus infection. Sherman KE, Flamm SL, Afdhal NH, et al. N Engl J Med. 2011 Sep 15;365(11):1014-24.

http://www.ncbi.nlm.nih.gov/pubmed/21916639

Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Ann Intern Med. 2011 Sep 20;155(6):353-60.

http://www.ncbi.nlm.nih.gov/pubmed/21930852

Low risk for hepatitis C seroconversion in methadone maintenance treatment. Peles E, Schreiber S, Rados V, Adelson M. J Addict Med. 2011 Sep;5(3):214-20.

http://www.ncbi.nlm.nih.gov/pubmed/21844836

Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C: Results From the WIN-R Trial. Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM. J Clin Gastroenterol. 2011 Sep;45(8):720-6.

http://www.ncbi.nlm.nih.gov/pubmed/21836471

Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: Final results of APPROACH (A Prospective study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada). Myers RP, Cooper C, Sherman M, et al. Can J Gastroenterol. 2011 Sep;25(9):503-10.

http://www.ncbi.nlm.nih.gov/pubmed/21912762

Association of hepatitis C virus infection and malnutrition-inflammation complex syn-drome in maintenance hemodialysis patients. Tsai HB, Chen PC, Liu CH, et al. Nephrol Dial Transplant. 2011 Sep 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21896499

Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells. Arends JE, Hoepelman AI, Nanlohy NM, et al. Apoptosis. 2011 Sep;16(9):959-66. doi: 10.1007/s10495-011-0620-2.

http://www.ncbi.nlm.nih.gov/pubmed/21667042

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon -alpha based therapy in HCV type-1 infection. Weich V, Herrmann E, Chung TL, et al. J Gastroenterol. 2011 Sep 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21912897

Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Shoeb D, Rowe IA, Freshwater D, et al. Eur J Gastroenterol Hepatol. 2011 Sep;23(9):747-53.

http://www.ncbi.nlm.nih.gov/pubmed/21691208

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. Sinn DH, Kim YJ, Lee ST, et al. J Gastroenterol Hepatol. 2011 Sep;26(9):1374-9. doi: 10.1111/j.1440-1746.2011.06744.x.

http://www.ncbi.nlm.nih.gov/pubmed/21501223

Basic and Applied Science, Pre-Clinical Studies

Alteration of hepatic nuclear receptor-mediated signaling pathways in HCV patients with and without a history of alcohol drinking. Wu C, Gilroy R, Taylor R, et al. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24645. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21898497

T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic hepatitis B and C. Dimitropoulou D, Karakantza M, Tsamandas AC, et al. In Vivo. 2011 Sep-Oct;25(5):833-40.

http://www.ncbi.nlm.nih.gov/pubmed/21753143

Prohibitin is overexpressed in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length hepatitis C virus RNA. Dang SS, Sun MZ, Yang E, et al. Virol J. 2011 Sep 6;8(1):424. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21896168

Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. Toyoda H, Kumada T, Hayashi K, et al. J Med Virol. 2011 Sep;83(9):1559-64. doi: 10.1002/jmv.22145.

http://www.ncbi.nlm.nih.gov/pubmed/21739446

Cell-to-Cell Contact with Hepatitis C Virus-Infected Cells Reduces Functional Capacity of Natural Killer Cells. Yoon JC, Lim JB, Park JH, Lee JM. J Virol. 2011 Sep 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21937646    

HIV/HCV Coinfection

Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. Winnock M, Bani-Sadr F, Pambrun E, et al . Vaccine. 2011 Sep 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21920402

Hip bone geometry in HIV/HCV-co-infected men and healthy controls. Walker Harris V, Sutcliffe CG, Araujo AB, et al. Osteoporos Int. 2011 Sep 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21901477

Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.

Bharti AR, Letendre SL, Wolfson T, et al. J Clin Virol. 2011 Sep 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21924674

Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G. J Clin Virol. 2011 Sep 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21924673

HIV and hepatitis C coinfection: pathogenesis: microbial translocation. Page EE, Nelson M, Kelleher P. Curr Opin HIV AIDS. 2011 Sep 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21918438

HIV-1 co-infection and morphine co-exposure severely dysregulate HCV-induced hepatic pro-inflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host-defenses. El-Hage N, Dever SM, Fitting S, Ahmed T, Hauser KF. J Virol. 2011 Sep 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21900165

Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Spengler U. Curr Opin HIV AIDS. 2011 Sep 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21918437

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Vivithanaporn P, Nelles K, Deblock L, Newman SC, Gill MJ, Power C. J Neurol Sci. 2011 Sep 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21925684

The Impact of Hepatitis C Coinfection on Kidney Disease Related to Human Immuno-deficiency Virus (HIV): A Biopsy Study. George E, Nadkarni GN, Estrella MM, et al. Medicine (Baltimore). 2011 Sep;90(5):289-95.

http://www.ncbi.nlm.nih.gov/pubmed/21857365

The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. Eslam M, López-Cortés LF, Romero-Gomez M. Curr Opin HIV AIDS. 2011 Sep 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21934619

Alterations in Immune Function are Associated with Liver Enzyme Elevation in HIV and HCV Co-infection after Commencement of Combination Antiretroviral Therapy. Cameron BA, Emerson CR, Workman C, Kelly MD, Lloyd AR, Post JJ. J Clin Immunol. 2011 Sep 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21932111

The effect of hepatitis C treatment and HIV coinfection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Matser A, Urbanus A, Geskus R, et al. Addiction. 2011 Sep 15. doi: 10.1111/j.1360-0443.2011.03654.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21919987

Complementary and Alternative Medicine

In vitro antiviral activities of extracts derived from Daucus maritimus seeds. Miladi S, Abid N, Debarnôt C, et al. Nat Prod Res. 2011 Sep 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21895456

Epidemiology, Diagnostics, and Miscellaneous Works

Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. J Clin Gastroenterol. 2011 Sep 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21934527

Public Health Implications of Rapid Hepatitis C Screening With an Oral Swab for Community-Based Organizations Serving High-Risk Populations. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Am J Public Health. 2011 Sep 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21940910

The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Martin NK, Vickerman P, Miners A, et al. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24656. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21898506

Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: New algorithms are more precise and entirely non-invasive. Boursier J, de Ledinghen V, Zarski JP, et al. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24654. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21898504

Fast DNA and protein microarray tests for the diagnosis of hepatitis C virus infection on a single platform. Ember SW, Schulze H, Ross AJ, et al. Anal Bioanal Chem. 2011 Sep 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21881881

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.

Hatzakis A, Wait S, Bruix J, et al. J Viral Hepat. 2011 Sep;18 Suppl 1:1-16. doi: 10.1111/j.1365-2893.2011.01499.x.

http://www.ncbi.nlm.nih.gov/pubmed/21824223

Liver Cancer

Factors affecting prognosis of small hepatocellular carcinoma in Taiwanese patients follow-ing hepatic resection. Ko CJ, Chien SY, Chou CT, Chen LS, Chen ML, Chen YL. Can J Gastroenterol. 2011 Sep;25(9):485-91.

http://www.ncbi.nlm.nih.gov/pubmed/21912759

Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. Kobayashi T, Itamoto T, Tashiro H, et al. J Hepatobiliary Pancreat Sci. 2011 Sep;18(5):689-99.

http://www.ncbi.nlm.nih.gov/pubmed/21445633

Hepatitis C Virus-Induced Cancer Stem Cell-like Signatures in Cell Culture and Murine Tumor Xenografts. Ali N, Allam H, May R, et al. J Virol. 2011 Sep 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21937640

Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C. Sterling RK, Wright EC, Morgan TR, et al. Am J Gastroenterol. 2011 Sep 20. doi: 10.1038/ajg.2011.312. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21931376

Hepatocellular carcinoma in HIV hepatitis C virus. Puoti M, Rossotti R, Garlaschelli A, Bruno R. Curr Opin HIV AIDS. 2011 Sep 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21934618

The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. Zhang X, Ryu SH, Xu Y, et al. J Clin Virol. 2011 Sep 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21925935